Ziftomenib with chemotherapy for children with relapsed leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a new drug called ziftomenib to standard chemotherapy can help children whose leukemia has come back or not responded to treatment. It is for children with certain genetic changes in their leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 0 and 21 years old and weigh at least 5 kg.
- Have acute leukemia with a specific genetic change (KMT2A, NPM1, or NUP98) that has come back or not responded to treatment.
- Have leukemia cells that can be measured in the bone marrow (at least 5% blasts).
- Be well enough physically (score of 60 or higher on a standard activity scale).
- Have adequate kidney, liver, and heart function.
- Have recovered from previous treatments and meet waiting periods after prior therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This Phase 1/2 trial tests bleximenib, a targeted medicine, for people whose acute leukemia has specific gene changes and has come back or does not respond to treatment. It may help by attacking these leukemia-specific targets when other treatment options have run out.
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Hear when a new Relapsed/Refractory KMT2A-r Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.